Stablix, Seeking to Stabilize Instead of Degrade Proteins, Raises $63M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
All Inclusive Medicine Needs More Diverse Genomic Data
Kidney Companies Taking Pages from Precision Oncology Playbook